Biomea Fusion Inc. has announced updated preliminary clinical data from its ongoing Phase I COVALENT-103 trial of the covalent FLT3 inhibitor BMF-500, aimed at treating adults with relapsed or refractory acute leukemia. The findings will be presented in a poster presentation at the European Hematology Association 2025 Congress in Milan, Italy, on Saturday, June 14. The study involves 27 patients, with a focus on those with FLT3-mutant acute myeloid leukemia. Results indicate that 9 out of 11 efficacy-evaluable patients showed significant bone marrow blast reduction, with five achieving over 50% reduction. Biomea Fusion plans to explore strategic partnerships to further develop BMF-500 following the completion of this trial phase.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。